AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

Analyst Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments. Vandana Singh US Stock Futures Fall As ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a Dividend King with over 50 consecutive annual dividend raises. The streak ...

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AbbVie generated $56 billion in revenue, achieving an operating profit of $12 billion and a net income of $4.3 billion, ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Guggenheim on April 29, 2025. The analyst firm set a price target for $216.00 expecting ABBV to rise to within 12 months (a possible ...

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. AbbVie is expected to post earnings of $3.11 ...